The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: Retrospective analysis of 144 patients

Breast Cancer Research and Treatment

Volumn 138, Issue 3, 2013, Pages 783-794

  Hurley, Judith ^a   Reis, Isildinha M ^b   Rodgers, Steven E ^a   Gomez Fernandez, Carmen ^a   Wright, Jean ^a   Leone, Jose Pablo ^c   Larrieu, Rene ^d   Pegram, Mark D ^e  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Neoadjuvant therapy; Platinum salts; Triple negative

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SIZE; CANCER STAGING; CANCER THERAPY; CLINICAL FEATURE; CONTROLLED STUDY; DRUG RESPONSE; DRUG TOLERABILITY; ETHNICITY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PALPATION; PATHOLOGIC COMPLETE RESPONSE; PATIENT INFORMATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RACE; RETROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST CANCER; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; CARBOPLATIN; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 84877826465     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2497-y     Document Type: Article

References (41)

1. EBCTCG (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717
2. Perou CM, Sorlie T, Elsen MB et al (2000) Molecular portraits of human breast tumors. Nature 406:747-752
3. Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874
4. Fulford LG, Easton DF, Reis-Filho JS et al (2008) Specific morphologic features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of the breast. Histopathology 49:22-34
5. Rahka E, Reis-Filho J, Ellis I (2008) Basal-like breast cancer: a critical review. J Clin Oncol 26(15):2568-2581
6. Banerjee S, Reis-Filho JS, Ashley S et al (2006) Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol 59:729-735
7. Van de Rijn M, Perou CM, Tibshirani R et al (2002) Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161:1991-1996
8. Abd El-Rehim DM, Pinder SE, Paish CE et al (2004) Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 203:661-671
9. Livasy CA, Karaca G, Nanda R et al (2006) Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19:264-271
10. Nielsen TO, Hsu FD, Jensen K et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367-5537
11. Carey L, Winer E, Viale G et al (2010) Triple-negative breast cancer: disease entitiy or title of convenience. Nat Rev Clin Oncol 7:683-692
12. Dent R, Trudeau M, Pritchard K et al (2007) Triple negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15):4429-4434
13. Gluz O, Liedtke C, Gottschalk N et al (2009) Triple-negative breast cancer - current status and future directions. Ann Oncol 20(12):1913-1927
14. Schneider B, Winer E, Foulkes W et al (2008) Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 14(24):8010-8018
15. Carey L, Perou C, Livasy C et al (2006) Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 295(21):2492-2502
16. Nanda Rita (2011) "Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers. Semin Oncol 38(2):254-262
17. Miyoshi Y, Murase K, Oh K (2008) Basal-like subtype and BRCA1 dysfunction in breast cancer. Int J Clin Oncol 13:395-400
18. Quinn J, Kennedy RD, Mullan P et al (2003) BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 63:6221-6228
19. Shafee N, Smith C, Wie S et al (2008) Cancer stem cells contribute to cisplatin resistance in BRCA1/p53-mediated mouse mammary tumors. Cancer Res 68(9):3243-3250
20. Bhattacharyya A, Ear U, Kollers B et al (2000) The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 275(31):23899-23903
21. Kennedy RD, Quinn J, Mullan PB et al (2004) The role of BRCA1 in the cellular response to chemotherapy. JNCI 96(22):1659-1669
22. Farmer H, McCabe N, Lord C et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-920
23. Foulkes W (2006) BRAC1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer 5:135-142
24. Gray R (1988) A class of K-sample tests for comparing the cumulative incidence of competing risk. Ann Stat 16:1141-1154
25. Fine JP, Gray R (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509
26. Parmar MKB, Machin D (1995) Survival analysis: a practical approach. Wiley, Cambridge
27. Fisher B, Brown A, Mamounas E et al (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483-2493
28. Kuerer HM, Newman LA, Smith TL et al (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469
29. Morrell L, Lee Y, Hurley J et al (1998) A Phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin in the treatment of patients with locally advanced breast cancer. Cancer 82:503-511
30. Carey L, Dees C, Sawyer L et al (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13(8):2329-2334
31. Liedtke C, Mazouni C, Hess K et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple negative breast cancer. J Clin Oncol 26(8):1275-1281
32. Dawood S, Briglio K, Kau S et al (2009) Triple negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol 27(2):220-226
33. Falo C, Moreno A, Varela M et al (2007) HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF. J Cancer Res Clin Oncol 133:423-429
34. Egawa C, Miyoshi Y, Takamura Y et al (2001) Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. Int J Cancer 95:255-259
35. Frasci G, Comella P, Rinaldo M et al (2009) Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple negative large operable breast cancer. Ann Oncol 20:1185-1192
36. Sirohi B, Arnedos M, Popat S et al (2008) Platinum based chemotherapy in triple-negative breast cancer. Ann Oncol 19:1847-1852
37. Yerulshalmi R, Hayes MM, Gelmon K et al (2009) A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and clinical correlation with biomarkers. Clin Breast Cancer 9(3):166-171
38. Byrski T, Huzarski T, Dent R et al (2008) Response to neoadjuvant therapy with cisplatin an BRCA1 positive breast cancer. Breast Cancer Res Treat 115(2):359-363
39. Silver D, Richardson AL, Ecklung A et al (2010) Efficacy of neoadjuvant cisplatin in triple negative breast cancer. J Clin Oncol 28(7):1145-1153
40. Rosell R, Gatzemeier U, Betticher DC et al (2002) Phase III randomized trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small cell lung cancer: a cooperative multinational trial. Ann Oncol 13:1539-1549
41. Ardizzoni A, Boni L, Tiseo M et al (2007) Cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 99(11):847-857